FDA advisers vote in favor of full approval for Pfizer’s COVID pill Paxlovid

Advisers to the U.S. health regulator on Thursday voted in favor of recommending a full approval for Pfizer’s COVID-19 pill Paxlovid in adults at high risk of progression to severe disease.

PFIZER’S COVID-19 DRUG PAXLOVID IN SHORT SUPPLY IN CHINA

Paxlovid, Pfizer’s anti-viral medication to treat the coronavirus disease (COVID-19), is displayed in this picture illustration taken on Oct. 7, 2022 (REUTERS/Wolfgang Rattay/Illustration)

The Food and Drug Administration’s panel of external advisers voted 16-to-1 in favor of the drug’s benefits outweighing its risk for some adults with mild-to-moderate COVID-19.